Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 3
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of a…
Severe Hypertriglyceridemia
Estimated
~$10 – $8,750
Arrowhead PharmaceuticalsNCT06880770
Phase 2
A Phase 2, Open-label Trial Evaluating the Safety, Tolerability and Efficacy of ION775 in Adults With Hypertriglyceridemia
The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and se…
HypertriglyceridemiaSevere Hypertriglyceridemia
Estimated
~$10 – $8,750
Ionis Pharmaceuticals, Inc.NCT07604974
Phase 1
A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are ref…
CardiovascularMetabolic DiseaseDyslipidemias+7 more
Estimated
~$10 – $8,750
CRISPR Therapeutics AGNCT07491172
Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in parti…
Severe Hypertriglyceridemia
Estimated
~$10 – $7,500
Eli Lilly and CompanyNCT07269210